Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. reports developments for its clinical-stage biotechnology program in fibro-inflammatory diseases. Recurring updates center on nebokitug, an antibody targeting CCL24, and its clinical evaluation in primary sclerosing cholangitis through the SPRING trial, related open-label extension data, biomarker findings, macrophage-mediated mechanism research, and peer-reviewed or medical-meeting presentations.
Company news also covers financial results, corporate updates, regulatory interactions with agencies, preparations for later-stage development, strategic partnering discussions, capital-raising activity involving American Depositary Shares, and participation in healthcare and rare-disease investor conferences.
Chemomab Therapeutics (Nasdaq:CMMB) reported Q1 2026 results and new nebokitug data in primary sclerosing cholangitis (PSC).
Proteomic and gene-expression analyses from the Phase 2 SPRING trial showed dose-dependent, statistically significant reductions in multiple fibrotic and inflammatory pathways, including in PSC patients with co-existing IBD. Cash was $8.0 million, with runway expected through Q1 2027; Q1 net loss was $1.8 million versus $3.3 million a year earlier, with R&D expenses reduced to $0.9 million from $2.5 million.
Chemomab (NASDAQ: CMMB) reported 2025 year-end results and a corporate update highlighting a successful FDA End-of-Phase 2 meeting for nebokitug and alignment on a single pivotal Phase 3 pathway in primary sclerosing cholangitis (PSC).
Key operational highlights include multiple scientific presentations, issued patents, senior clinical appointments, and publication of Phase 2 SPRING data. Financials: cash of $10.4M (12/31/2025) with a stated runway to end of Q1 2027, full-year R&D of $5.8M, G&A of $3.7M, and a 2025 net loss of $9.0M.
Chemomab Therapeutics (Nasdaq: CMMB) said CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:00 am ET.
The corporate presentation will be webcast live and available on the company's investor relations website for 90 days; management will also hold one-on-one investor meetings.
Chemomab (Nasdaq: CMMB) announced publication (Nov 19, 2025) of Phase 2 SPRING results for nebokitug in primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. The double-blind randomized study (n=76) evaluated IV nebokitug 10 mg/kg and 20 mg/kg vs placebo up to 15 weeks with an open-label extension to 48 weeks.
Key findings: nebokitug was generally safe and well tolerated through 48 weeks; dose-dependent biomarker improvements were observed, with the 20 mg/kg arm and patients with moderate/advanced fibrosis showing numerical and durable reductions in ELF, PRO-C3, and statistically significant reductions in liver stiffness at 15 weeks. Results support advancement to a Phase 3 registration trial.
Chemomab (Nasdaq: CMMB) announced that co-founder and CEO Adi Mor, PhD will present at Oppenheimer’s Movers in Rare Disease Summit on December 11, 2025 in New York City.
The company will deliver a corporate overview at 2:15–2:45 pm EST at the Sofitel Hotel and will be available for one‑on‑one investor meetings with registered attendees. Investors should contact their Oppenheimer representative to register and schedule meetings.
Chemomab (Nasdaq: CMMB) reported Q3 2025 results and a corporate update on Nov 20, 2025. Management said FDA and EMA provided alignment that a single nebokitug Phase 3 registration trial using a composite clinical event endpoint could support approval, and Phase 3 design is near completion.
Data from the Phase 2 SPRING open-label extension up to 48 weeks showed favorable safety and consistent improvements in inflammatory and fibrotic biomarkers. Cash, cash equivalents and short-term deposits were $10.2M as of Sept 30, 2025, funding operations through end of Q4 2026.
Chemomab (Nasdaq: CMMB) announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis (PSC) will be presented at AASLD The Liver Meeting® on November 10, 2025. Open-label extension (up to 48 weeks) data show nebokitug was well tolerated with sustained or continued improvements in inflammatory and fibrosis biomarkers, including ELF score and liver stiffness, especially at 20 mg/kg. Mechanistic analyses report dose-dependent reductions in macrophage-related proteins, a dose-dependent increase in MST1, and correlations between MST1/CCL24 changes and liver stiffness. All three posters were designated Posters of Distinction.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dr. Adi Mor will deliver a prerecorded corporate presentation, which will be available from September 5, 2025, at 7:00 am ET for 90 days via webcast. The company's management team will also conduct one-on-one investor meetings on September 8-9, 2025.
Chemomab Therapeutics (Nasdaq: CMMB) reported Q2 2025 financial results and provided updates on its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company is preparing for Phase 3 trials while pursuing strategic partnerships to optimize development resources. Key financial metrics include cash position of $9.5 million as of June 30, 2025, with runway through Q2 2026.
Notable developments include FDA alignment on CMC standards and toxicology testing requirements, new patent issuances in China and Russia, and multiple presentations of Phase 2 SPRING trial data at major scientific meetings. The company also announced plans to implement an ADS ratio change from 1:20 to 1:80 effective August 26, 2025, essentially functioning as a 1:4 reverse split for ADS holders.
Chemomab Therapeutics (Nasdaq: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at BSG Live'25. The data was presented by Principal Investigator Dr. Douglas Thorburn at the British Society for Gastroenterology annual meeting in Glasgow.
The trial demonstrated that nebokitug was well-tolerated over 48 weeks of treatment, with a safety profile comparable to placebo during the initial 15-week double-blind portion. In patients with moderate to advanced disease, the drug showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects.
The open-label extension portion, lasting up to an additional 33 weeks, revealed sustained improvement in fibrosis markers and other PSC-related parameters. These positive results support advancement to Phase 3 trials, potentially positioning nebokitug as the first approved therapy for PSC.